Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study

Background: beta-Amyloid has recently been discovered in the myocardium of patients with Alzheimer's disease (AD). Whether genetic variation in apolipoprotein E (APOE) epsilon 4, a common variant associated with Alzheimer's disease, is associated with incident heart failure (HF), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac structure and function is unknown. Methods and Results: We studied 15,064 White and Black participants in the Atherosclerosis Risk in Communities, relating genotype status at visit 1 (1987-1989) to incident HF hospitalization using Cox regression. At visits 2, 4, and 5, we assessed NT-proBNP levels by genotype. At visits 3 and 5, we related A beta peptides to incident HF. At visit 5 (2011-2013, n = 6251), we assessed the relationship of genotype with prevalent HF and echocardiographic parameters. The mean participant age was 54.7 +/- 5.8 years, 45% were men, and 73% were White. At visit 5, there was no difference in prevalent HF by genotype. The APOE epsilon 4 carriers did not have increased risk for HF hospitalization. The APOE epsilon 4 genotype was not associated with cardiac structure and function or NT-proBNP levels. The A beta peptides were not associated with incident HF after multivariable adjustment. Conclusions: A genetic predisposition to Alzheimer's disease through APOE epsilon 4 is not associated with an increased prevalence of HF, HF hospitalization, myocardial remodeling, or biochemical evidence of HF.

Automated summary

The genetic predisposition to Alzheimer's disease through APOEε4 is not associated with an increased prevalence of HF, HF hospitalization, myocardial remodeling, or biochemical evidence of HF.